Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.23 (market cap $3.62B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: iShares MSCI United Kingdom (FTSE) is the larger of the two by market cap, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EWU | RXRX | |
|---|---|---|
Market Cap | $3.62B | $2.14B |
Volume | 923,896 | 30,789,535 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $6.79 |
52-Week Low | $41.34 | $2.84 |
Typical Hold Time | 46 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU, the iShares MSCI United Kingdom ETF, is trading at $45.93, down 0.95% amid broader market pressures. Technical indicators show a bearish trend with moving averages signaling sell pressure, though RSI levels suggest potential oversold conditions. The fund faces headwinds from UK economic concerns including rising gilt yields and inflation pressures, while recent government housing initiatives provide some sector-specific support.
The outlook remains cautious as UK economic vulnerabilities and rising borrowing costs weigh on sentiment. Investment opportunity exists for long-term investors seeking UK exposure at discounted levels, though near-term risks include persistent inflation and political uncertainty surrounding the upcoming budget announcement.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
